Cost-effectiveness analysis of sintilimab plus pemetrexed and platinum versus chemotherapy alone as first-line treatment in metastatic non-squamous non –small cell lung cancer in China

In frst-line treatment of advanced or metastatic nonsquamous non-small-cell lung cancer (NSCLC), the ORIENT-11 study demonstrated a signifcant progression-free survival and overall survival for sintilimab plus...

Source: Health Economics Review - December 30, 2022 Category: Health Management Authors: Huiqin Liu, Ying Wang and Qi He Tags: Research Source Type: research